Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Quarterly results
PORTOLA PHARMACEUTICALS INC (PTLA) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/11/2020 8-K Quarterly results
02/26/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update – Andexxa®/Ondexxya® Net Product Revenues of $35.7 million, a 32% Increase Over the Prior Quarter – – Andexxa Now Stocked in Approximately 550 U.S. Hospitals; 76% of U.S. Sales from Reorders – – Expanded Market Opportunity with Strong Initial Ondexxya Demand in Europe – – Strengthened Balance Sheet; Added Net Proceeds of $245 million in Third Quarter–"
08/07/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 7, 2019 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pr...",
"Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update"
05/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 8, 2019 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update"
03/01/2019 8-K Quarterly results
11/07/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 7, 2018 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update"
08/09/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 9, 2018 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pr...",
"Portola Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update"
05/09/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update"
02/28/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update"
11/06/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 6, 2017 Portola Pharmaceuticals, Inc. Delaware 001-35935 20-0216859 270 E. Grand Avenue South San Francisco, California 94080 Registrant's telephone number, including area code: 246-7300 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ ...",
"Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., November 6, 2017—Portola Pharmaceuticals Inc. ® will today report financial results and provide a corporate update for the quarter ended September 30, 2017. “Following FDA approval of our first product, Bevyxxa, our team has been working diligently to bring this important new medicine to patients in need, and we are pleased to report good progress with the FDA on achieving product release,” said Bill Lis, chief executive officer of Portola. “We are also continuing to advance AndexXa, the first-ever Factor Xa inhibitor antidote. This treatment is highly anticipated by the medical community and we are continuing discussions with U.S. and European regulatory authorit..."
08/09/2017 8-K Quarterly results
Docs: "Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update"
05/08/2017 8-K Form 8-K - Current report
02/28/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "Portola Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update"
08/09/2016 8-K Form 8-K - Current report
05/05/2016 8-K Form 8-K - Current report
02/25/2016 8-K Form 8-K - Current report
11/09/2015 8-K Form 8-K - Current report
08/04/2015 8-K Form 8-K - Current report
05/06/2015 8-K Form 8-K - Current report
03/02/2015 8-K Form 8-K - Current report
11/10/2014 8-K Form 8-K - Current report
08/06/2014 8-K Form 8-K - Current report
05/12/2014 8-K Form 8-K - Current report
02/27/2014 8-K Form 8-K - Current report
11/12/2013 8-K Form 8-K - Current report
08/15/2013 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy